Table 1.
Sample characteristics
| Participants (%), median (IQR), or mean (SD) |
|
|---|---|
| Hepatitis Cþ | 16 (34) |
| Age (years) | 49 (25–66) |
| Sex Male | 37 (79) |
| Female | 10 (21) |
| Ethnic/racial category | |
| African American | 15 (32) |
| Caucasian | 9 (19) |
| Hispanic | 16 (34) |
| Other/not reported | 7 (15) |
| Years of education | 12.3 (2.0) |
| Preferred route of opioid administration | |
| Heroin | |
| Intranasal | 14 (30) |
| Intravenous | 8 (17) |
| Prescription opioids | |
| Oral | 25 (53) |
| Daily equivalent morphine dose (mg)a | 183.9 (162.9) |
| Years of opioid use | 13.4 (12.7) |
| BDI score | 12.1 (9.5) |
| BPI ratings | |
| BPI pain severity rating | 6.1 (2.0) |
| BPI pain interference rating | 5.0 (2.5) |
| SF-36 scales | |
| Physical functioning | 55.5 (33.5) |
| Role limitations due to physical functioning | 51.6 (46.4) |
| Role limitations due to emotional problems | 66.3 (41.7) |
| Vitality | 52.8 (21.4) |
| Emotional well-being | 68.5 (19.2) |
| Social functioning | 67.5 (29.9) |
| Pain | 41.3 (24.8) |
| General health | 65.4 (23.2) |
a
Based on reported use over the past month.
b
Based on most preferred method of administration.